Journal article

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study

JY Reginster, E Seeman, MC De Vernejoul, S Adami, J Compston, C Phenekos, JP Devogelaer, MD Curiel, A Sawicki, S Goemaere, OH Sorensen, D Felsenberg, PJ Meunier

Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 2005

Abstract

BACKGROUND: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to assess its efficacy and safety in preventing nonvertebral fractures also. METHODS: Strontium ranelate (2 g/d) or placebo were randomly allocated to 5091 postmenopausal women with osteoporosis in a double-blind placebo-controlled 5-yr study with a main statistical analysis over 3 yr of treatment. FINDINGS: In the entire sample, relative risk (RR) was reduced by 16% for all nonvertebral fractures (P = 0.04), and by 19% for major fragility fractures (hip, wrist, pelvis and sacrum, ribs and ste..

View full abstract

University of Melbourne Researchers